Lexeo Therapeutics (NASDAQ:LXEO) Reaches New 12-Month High – Here’s What Happened

Lexeo Therapeutics, Inc. (NASDAQ:LXEO)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $10.90 and last traded at $10.7050, with a volume of 102872 shares traded. The stock had previously closed at $10.35.

Analysts Set New Price Targets

Several research analysts have recently commented on LXEO shares. Chardan Capital reissued a “buy” rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a report on Thursday, December 11th. Guggenheim assumed coverage on shares of Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target on the stock. Leerink Partners increased their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Raymond James Financial started coverage on Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $19.33.

Lexeo Therapeutics Trading Up 4.3%

The stock has a 50 day simple moving average of $9.34 and a 200-day simple moving average of $6.54. The firm has a market cap of $794.50 million, a PE ratio of -4.03 and a beta of 1.76.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. On average, equities research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Insiders Place Their Bets

In related news, insider Eric Adler sold 3,382 shares of the stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the sale, the insider directly owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the sale, the chief executive officer owned 242,118 shares of the company’s stock, valued at $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 24,646 shares of company stock valued at $221,037. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently modified their holdings of the company. Balyasny Asset Management L.P. acquired a new stake in Lexeo Therapeutics during the second quarter worth approximately $16,117,000. Frazier Life Sciences Management L.P. raised its position in shares of Lexeo Therapeutics by 363.1% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after purchasing an additional 3,469,210 shares during the period. Affinity Asset Advisors LLC increased its holdings in shares of Lexeo Therapeutics by 142.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company’s stock worth $14,429,000 after acquiring an additional 2,108,474 shares during the period. Vestal Point Capital LP raised its stake in shares of Lexeo Therapeutics by 184.1% in the 2nd quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock worth $12,977,000 after buying an additional 2,091,912 shares in the last quarter. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Lexeo Therapeutics by 955.7% during the third quarter. ADAR1 Capital Management LLC now owns 1,531,953 shares of the company’s stock valued at $10,172,000 after buying an additional 1,386,844 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.